Actively Recruiting
Study of AB801 With Chemotherapy and Immunotherapy for Borderline Resectable, Locally Advanced, or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
Led by Jonsson Comprehensive Cancer Center · Updated on 2026-08-20
46
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, side effects, best dose, and effectiveness of AB801 combined with chemotherapy and immunotherapy in patients with borderline resectable, locally advanced, or metastatic cholangiocarcinoma or pancreatic adenocarcinoma. AB801 targets a protein called AXL, which is involved in tumor growth, spread, and resistance to treatments. This phase I trial aims to assess how AB801 affects these cancers when used alongside standard therapies. The study has two groups one for patients with cholangiocarcinoma receiving AB801 orally daily with gemcitabine, cisplatin, and durvalumab intravenously every 21 days and another for patients with pancreatic cancer receiving AB801 orally daily with zimberelimab and a combination chemotherapy regimen called FOLFIRINOX every 28 days. Both treatment plans last up to 24 weeks unless the disease progresses or side effects become unacceptable. Patients will have CT or MRI scans and tissue biopsies during the trial. Participants will be monitored with imaging and biopsies throughout treatment. After completing therapy, follow-up visits occur at 30 and 90 days, then every three months to track safety and treatment effects. Researchers will measure dose-limiting toxicities, response rates, progression-free survival, surgery rates, and changes in tumor and blood markers. The total duration of participation varies based on treatment and follow-up schedules.
CONDITIONS
Brief Title
AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here